Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
XultophyⓇ has documented strong efficacy across the
treatment cascade
Slide 71
DUAL I
Add-on to
XultophyⓇ key clinical results
DUAL II
Add-on to
DUAL III
Switch from GLP-1
DUAL IV
Add-on to SU ±
DUAL V
Switch from insulin
metformin ± Pio
n = 833
metformin ± basal
n = = 292
insulin
metformin
n = 289
glargine
n = 557
n =
: 199
Mean trial start HbA1c (%)
8.3
8.7
7.8
7.9
8.4
Mean trial end HbA1c (%)
6.4
6.9
6.4
6.4
6.6
HbA1c change (%)
-1.9
-1.9
-1.3
-1.45
-1.8
% to target < 7% (%)
80.6
60.3
75.3
79.2
71.6
% to target < 6.5% (%)
69.7
45.2
63.0
64.0
55.4
Confirmed hypoglycaemia
180.2
153.4
282
351.7
343.3
(Episodes per 100 PYE)
Weight change (kg)
-0.5
-2.7
+2.0
+0.5
-1.4
Note: Typical confirmed hypoglycaemia event rates for treatment with basal insulin are 142-369 episodes per 100 PYE (based on insulin glargine event rates from trials NN1250-3586, 3579 and 3672)
where the FPG target and hypoglycaemia definition is similar to the DUAL trials
changing
diabetes
novo nordiskView entire presentation